December 13, 2007

Independent Research Group Reports that Pressure BioSciences' Award Winning ProteoSolve-LRS Technology Played a Significant Role in the Identification of Potential Biomarkers in Breast and Colon Cancer Tissue

WEST BRIDGEWATER, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that scientists at the New York University (NYU) School of Medicine have reported that their use of the Company's patent-pending, award winning technology (ProteoSolve-LRS) was in large part responsible for the identification of potential biomarkers in breast and colon cancer tissue. ProteoSolve-LRS is the Company's recently- released method for the detergent-free extraction of proteins from lipid-rich and other tissues. Results of the studies were presented during the past two days at the LC-MS Course and Symposium, Robinson College, Cambridge, England by Dr. Paul Pevsner of the NYU School of Medicine Department of Pharmacology.

The study of proteins (proteomics) may lead to a better understanding of many disease states, such as cancer. To that end, proteins usually need to be extracted from the cells and tissues in which they reside to be effectively studied. Unfortunately, there are technical challenges that can adversely affect the extraction of proteins from cells and tissues, especially from those that are rich in lipids. These extraction challenges might hinder discoveries that could foster new therapeutics and diagnostics. The Company believes that its ProteoSolve-LRS method, when used in combination with its pressure cycling technology (PCT), will often allow proteomics researchers to achieve more rapid, more reproducible, and higher quality protein extraction results when compared to other current methods. The Company further believes that this improved method for protein extraction should lead to an enhanced ability for researchers to find and identify new biomarkers of disease.

Dr. Paul H. Pevsner, principle investigator for the research studies, said: "Our studies showed that the combination of cycled high pressure (PCT) with the ProteoSolve-LRS kit, used in conjunction with other instrumentation in our laboratory, allowed us to identify potential biomarkers of breast and colon cancer. This is a significant finding, since these potential biomarkers may prove to be important indicators of disease detection and progression. It is possible that these findings may alter the current paradigm of histopathology tissue diagnosis for tumors. In the future, examination of biopsy tissue may require not only histopathology, but also mass spectrometry for complete diagnosis."

Dr. Pevsner continued: "The combination of PCT and ProteoSolve-LRS is particularly suited for the study of the small, often nano-quantities of samples that are usually available for

proteomic studies. The combination of this method with mass spectrometry instrumentation may become a method of choice for bio-molecular identification, not just in cancer, but in neurological and coronary diseases as well."

About The Frost & Sullivan Award

As announced on November 27, 2007, Frost and Sullivan named Pressure BioSciences the recipient of the 2007 North American Frost and Sullivan Award for Technology Innovation. The Award recognized PBI for "the development of a method for the detergent-free extraction of proteins from lipid-rich tissues. This novel approach combines the power of the Company's pressure cycling technology (PCT) with the innovative chemistry of its ProteoSolve-LRS kit, resulting in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling." Each year, Frost & Sullivan presents the North American Technology Innovation Award to the company that has demonstrated excellence in new products and technologies within their industry. The Award recognizes innovation through the launch of a broad line of emerging products and technologies.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the importance of ProteoSolve-LRS and PCT in the reported identification of potential biomarkers by the NYU School of Medicine; the possibility that the biomarkers identified by the NYU School of Medicine or any other biomarkers that might be discovered in the future could lead to new therapeutics and diagnostics; the advantages of ProteoSolve-LRS and PCT over other sample preparation methods; and the possibility that ProteoSolve-LRS and PCT may become the extraction method of choice for bio-molecular identification. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that due to the nature of the research being performed, other laboratories may not find the use of ProteoSolve-LRS and PCT to be as advantageous as reported by Dr. Pevsner and his colleagues; due to scientific and medical challenges, the possibility that the data generated by Dr. Pevsner and his colleagues or that may be generated by other researchers in the future may not be beneficial in the development of new therapeutics and diagnostics for breast and colon cancer or other diseases; that due to competitive products, services, and

technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Senior Vice President of Finance & CFO
Pressure BioSciences, Inc.
(508) 580-1818 (T)

SOURCE Pressure BioSciences, Inc.